ReviewStem cells international2025
Progress and Prospects in the Treatment of Lacrimal Gland Dysfunction Diseases: From Traditional Treatment Methods to Stem Cell and Organoid Therapies.
Review in Stem cells international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Lacrimal gland organoids: A systematic review on development, characterization, molecular profiling and translational potential in dry eye disease.Experimental eye research · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lacrimal gland (LG) dysfunction diseases are a type of disorder caused by various etiologies that damage the LG tissue, reducing lacrimal fluid secretion, triggering aqueous-deficient dry eye (ADDE), and causing a series of complications like keratoconjunctivitis sicca, potentially threatening vision. Our review summarizes the limitations and new progress of traditional treatment methods for LG dysfunction diseases. Meanwhile, we conduct in-depth analyses closely centered on the two emerging and cutting-edge research hotspots, namely stem cell therapy and organoid therapy. We have comprehensively evaluated the current research status regarding various stem cells, their derived extracellular vesicles, and LG organoid transplantation, further discussed the existing deficiencies, and subsequently put forward the prospective directions for future research. These include developing ophthalmic preparations of extracellular vesicles and LG stem cells or searching more efficient drug delivery systems, as well as culturing LG organoids that are highly similar to human lacrimal glands (LGs) in both function and microstructure through magnetic three-dimensional (3D) bioprinting technology and microfluidic 3D bioprinting technology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.